Mazdutide: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •6 known side effects documented
- •4 mild, 2 moderate, 0 severe
- •6 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Most commonly reported adverse event (~36% of patients). Predominantly mild to moderate, most frequent during dose escalation. The glucagon component may contribute to higher GI rates than pure GLP-1 agonists.
Reported in ~29% of patients. A pharmacological effect of GLP-1 receptor agonism that contributes to weight loss efficacy.
Reported in ~23% of patients. Most common during dose escalation with incidence declining over continued treatment. Mostly mild to moderate.
Reported in ~14% of patients. More frequent during dose escalation. Generally mild to moderate severity.
~10% incidence, primarily in T2D patients on concomitant insulin or sulfonylureas. Low risk in non-diabetic patients due to glucose-dependent insulin secretion.
Mild redness, swelling, or itching at injection site. Transient and self-resolving.
⛔Contraindications
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •Known hypersensitivity to mazdutide or excipients
- •Pregnancy and breastfeeding
- •Severe gastrointestinal disease (gastroparesis, IBD)
- •History of pancreatitis (use with caution)
⚠️Drug Interactions
- •Insulin and sulfonylureas: Increased hypoglycemia risk. Dose reduction of concomitant agents recommended when initiating mazdutide.
- •Oral medications: Delayed gastric emptying may affect absorption kinetics. Monitor time-sensitive oral medications.
- •Warfarin: Monitor INR closely due to potential absorption changes from delayed gastric emptying.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 5+ community reports
View community protocolsSafety Overview#
Mazdutide's safety profile has been characterized through Phase I, II, and III clinical trials enrolling thousands of patients. The adverse event profile is consistent with the GLP-1 receptor agonist class, with gastrointestinal symptoms predominating. Events are primarily mild to moderate, most frequent during dose escalation, and tend to decrease with continued treatment.
Gastrointestinal Side Effects#
The most prominent side effects of mazdutide are gastrointestinal, reflecting GLP-1 and glucagon receptor activation on the digestive system.
Diarrhea#
Diarrhea was the most frequently reported adverse event (~36% of patients vs placebo). This rate is notably higher than typically seen with pure GLP-1 agonists, suggesting the glucagon receptor component may contribute. However, the vast majority of cases were mild to moderate, no participants discontinued treatment due to diarrhea in Phase 1b, and incidence declined with continued treatment.
Nausea and Vomiting#
Nausea (23%) and vomiting (14%) are class effects of GLP-1 receptor agonists, mediated by central (brainstem area postrema) and peripheral (vagal afferent) mechanisms. These are most common during initial treatment and dose escalation. A meta-analysis confirmed higher risks vs placebo: nausea RR 4.22, vomiting RR 4.91. Despite elevated rates, treatment discontinuation due to GI events was uncommon.
Decreased Appetite#
Decreased appetite (29%) is a pharmacological effect contributing directly to weight loss. While classified as an adverse event, this represents a desired therapeutic outcome in obesity treatment.
Metabolic Effects#
Hypoglycemia#
Hypoglycemia (~10%) occurred predominantly in T2D patients on concomitant insulin or sulfonylureas. Risk is low in non-diabetic patients because mazdutide's insulin-secretagogue effect is glucose-dependent. Dose reduction of concomitant insulin or sulfonylureas is recommended when initiating mazdutide.
Heart Rate#
Small resting heart rate increases (2-4 bpm) are consistent with the GLP-1 agonist class. Clinical significance appears low based on available data.
Cardiac Conduction#
Mild, asymptomatic, transient cardiac conduction changes were detected on ECG in clinical trials, including supraventricular arrhythmias. These were rare and resolved spontaneously.
Pancreatic Safety#
As with all GLP-1 receptor agonists, pancreatitis is a theoretical concern. Incidence was low and comparable to placebo in mazdutide trials. Patients should report persistent severe abdominal pain. Long-term rodent toxicology with GLP-1 agonists shows species-specific C-cell effects (medullary thyroid carcinoma in rats) that have not been observed in humans, but a class-wide precaution applies.
Dose-Response Safety#
Higher doses correlate with more GI adverse events:
| Dose | Nausea | Diarrhea | Vomiting |
|---|---|---|---|
| 3-4 mg | ~15% | ~25% | ~8% |
| 6 mg | ~23% | ~36% | ~14% |
| 9 mg | ~30% | ~40% | ~18% |
| Placebo | ~5% | ~8% | ~3% |
Gradual dose titration (starting low, increasing every 4 weeks) improves tolerability.
Long-Term Considerations#
- Gallbladder events: Rapid weight loss increases cholelithiasis risk. Monitor for gallbladder symptoms.
- Lean body mass: Some lean mass loss accompanies fat loss. Long-term implications require study.
- Weight regain: GLP-1-based therapy discontinuation typically leads to weight regain. Mazdutide-specific data is limited.
- Bone density: Effects of sustained weight loss on bone mineral density need monitoring.
Monitoring Recommendations#
- Baseline: HbA1c, fasting glucose, lipid panel, liver function, pancreatic enzymes, thyroid function
- During treatment: Regular glucose monitoring (diabetic patients), periodic HbA1c, weight, liver function
- Symptom monitoring: GI symptoms, injection site reactions, pancreatitis signs, hypoglycemia signs
- Long-term: Body composition, bone density in at-risk populations, gallbladder symptoms
Evidence Gaps#
- Cardiovascular outcomes data (MACE endpoints) not yet available
- Long-term safety beyond 60 weeks not characterized
- Safety in severe renal or hepatic impairment not established
- Drug interaction studies limited
- Safety in pregnancy not studied
- Effects on fertility unknown
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Mazdutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.